NEW YORK (GenomeWeb News) - Bristol-Myers Squibb has licensed GeneGo’s software and database platforms for its pharmaceutical research programs, GeneGo said today.
Under the multi-year agreement, BMS will use "all major GeneGo products" for chemical and biological studies, GeneGo said. BMS researchers will use the company’s tools to analyze data and to build their own pathway maps using public, GeneGo, and proprietary data.
GeneGo said that BMS researchers will also use its products to overlay in-house interaction data over the company’s manually curated pathways.
GeneGo's software suite includes MetaCore, which is used to target and identify biomarkers for disease research; the MetaDrug platform, for studying metabolism and toxicity; and MetaBase, which holds data and information for the MetaCore product.
Financial terms of the agreement were not released.